Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 201–300 of 1,010
Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists
Crem, N. D., Peerlinck, K., Vanassche, T., Vanheule, K., Debaveye, B., Middeldorp, S., Verhamme, P. B., & Peetermans, M. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.030 · Cited by 114
Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD
Harel, Z., Sholzberg, M., Shah, P. S., Pavenski, K., Harel, S., Wald, R., Bell, C. M., & Perl, J. M. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040361 · Cited by 108
Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions
Kvasnička, T., Malíková, I., Zenáhlíková, Z., Kettnerova, K., Brzežková, R., Zima, T., Ulrych, J., Bříza, J., Netuka, I., & Kvasnička, J. (2017) · Current Drug Metabolism · doi:10.2174/1389200218666170518165443 · Cited by 113
Levy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 119
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 112
Noble, S., Matzdorff, A. C., Maraveyas, A., Holm, M., & Pisa, G. (2015) · Haematologica · doi:10.3324/haematol.2015.127126 · Cited by 106
Davies, G. A., Lazo‐Langner, A., Gándara, E., Rodger, M. A., Tagalakis, V., Louzada, M., Corpuz, R., & Kovacs, M. J. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.003 · Cited by 106
Prevention and Management of the Post-Thrombotic Syndrome
Makedonov, I., Kahn, S. R., & Galanaud, J. ‐. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040923 · Cited by 112
van Bellen, B., Bamber, L., Correa de Carvalho, F., Prins, M., Wang, M., & Lensing, A. W. A. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.879439 · Cited by 104
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
Mavrakanas, T. A., & Bounameaux, H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.12.007 · Cited by 117
Brown, D. G., Wilkerson, E. C., & Love, W. E. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.10.027 · Cited by 134
CSAR 2014: A Benchmark Exercise Using Unpublished Data from Pharma
Carlson, H. A., Smith, R. D., Damm-Ganamet, K. L., Stuckey, J. A., Ahmed, A., Convery, M. A., Somers, D. O., Kranz, M., Elkins, P. A., Cui, G., et al. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00523 · Cited by 103
Mantha, S. H., Laube, E., Miao, Y., Sarasohn, D. M. M., Parameswaran, R., Stefanik, S., Brar, G. S., Samedy, P., Wills, J., Harnicar, S. J., et al. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1429-1 · Cited by 104
Novel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis
Geisbüsch, C., Richter, D., Herweh, C., Ringleb, P. A., & Nagel, S. (2014) · Stroke · doi:10.1161/strokeaha.114.006167 · Cited by 103
The New Oral Anticoagulants in Clinical Practice
Gonsalves, W. I., Pruthi, R. K., & Patnaik, M. M. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.03.006 · Cited by 112
Anticoagulating obese patients in the modern era
Patel, J. P., Roberts, L. N., & Arya, R. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08826.x · Cited by 104
“This allows fixed dosing and these advantages are borne out in Phase III clinical trials for various indications (Connolly et al, 2009, 2011; Bauersachs et al, 2010).”
BackgroundPerzborn, E., Heitmeier, S., Laux, V., & Buchmüller, A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.017 · Cited by 100
Dufrost, V., Risse, J., Zuily, S., & Wahl, D. G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0623-7 · Cited by 99
Evaluation of bleeding in patients receiving direct oral anticoagulants
Hellenbart, E. L., Faulkenberg, K. D., & Finks, S. W. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s121661 · Cited by 112
Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Prins, M. H., Lensing, A. W. A., Prandoni, P., Wells, P. S., Verhamme, P. B., Beyer‐Westendorf, J., Bauersachs, R. M., Bounameaux, H., Brighton, T., Cohen, A. T., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017160 · Cited by 108
Creager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001415 · Cited by 256
Rohde, G., Stratmann, G., Hesse, C., Herth, N., Schwers, S., Perzborn, E., Lindhoff‐Last, E., & Mani, H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0832 · Cited by 98
The evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed · doi:10.2450/2015.0096-15 · Cited by 127
Moll, F. L., Baumgärtner, I., Jaff, M. R., Nwachuku, C., Tangelder, M. J. D., Ansel, G. M., Adams, G. L., Zeller, T., Rundback, J. H., GROSSO, M. A., et al. (2018) · Journal of Endovascular Therapy · doi:10.1177/1526602818760488 · Cited by 105
Acute pulmonary embolism: a concise review of diagnosis and management
Rayner, M., Darvall, J. N., & Hammerschlag, G. (2019) · Internal Medicine Journal · doi:10.1111/imj.14145 · Cited by 120
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Brandão, L. R., Albisetti, M., Halton, J., Bomgaars, L. R., Chalmers, E. A., Mitchell, L. G., Nurmeev, I. N., Svirin, P., Kuhn, T., Zapletal, O., et al. (2019) · Blood · doi:10.1182/blood.2019000998 · Cited by 105
Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries
Wheelock, K. M., Ross, J. S., Murugiah, K., Lin, Z., Krumholz, H. M., & Khera, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37288 · Cited by 104
Deep Vein Thrombosis of the Upper Extremity
Heil, J., Miesbach, W., Vogl, T. J., Bechstein, W. O., & Reinisch, A. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0244 · Cited by 122
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
Harder, S., & Graff, J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1510-z · Cited by 102
Hesse, C., Gertrud, S., Lindhoff‐Last, E., & Mani, H. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0667 · Cited by 97
Bleeding and antidotes in new oral anticoagulants
Majeed, A., & Schulman, S. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.001 · Cited by 99
Castellucci, L. A., Shaw, J. R., van der Salm, K., Erkens, P. M. G., Gal, G. L., Petrcich, W., & Carrier, M. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.007 · Cited by 100
Weishaupt, C., Strölin, A., Kahle, B. K., Kreuter, A., Schneider, S. W., Gerß, J., Eveslage, M., Drabik, A., & Goerge, T. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00251-3 · Cited by 97
The diagnosis and treatment of venous thromboembolism in Asian patients
Wang, K.-L., Yap, E. S., Goto, S., Zhang, S., Siu, C., & Chiang, C. (2018) · Thrombosis Journal · doi:10.1186/s12959-017-0155-z · Cited by 104
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Kreuziger, L. B., Jaffray, J., & Carrier, M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.002 · Cited by 102
Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)
Hepatobiliary Disease Study Group, C. S. O. G. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12970 · Cited by 106
Eichinger, S., Heinze, G., & Kyrle, P. A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000467 · Cited by 99
Advantages and limitations of the new anticoagulants
Schulman, S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12138 · Cited by 98
Hoffman, M., & Dickneite, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0431 · Cited by 101
Statin treatment and the risk of recurrent pulmonary embolism
Biere‐Rafi, S., Hutten, B. A., Squizzato, A., Ageno, W., Souverein, P. C., de Boer, A., Gerdes, V. E. A., Buller, H. R., & Kamphuisen, P. W. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht046 · Cited by 95
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
Geldhof, V., Vandenbriele, C., Verhamme, P. B., & Vanassche, T. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-21 · Cited by 98
“The efficacy and safety of the thrombin inhibitor dabigatran etexilate and the factor Xa inhibitors rivaroxaban, apixaban and edoxaban for the treatment and secondary prevention of VTE have been demonstrated in large phase III programs [1,3,14-18].”
BackgroundInfluentialHakeam, H. A., & Al-Sanea, N. A. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1465-x · Cited by 102
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa
Bauer, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04321.x · Cited by 104
Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study
Linkins, L., Warkentin, T. E., Pai, M., Shivakumar, S., Manji, R. A., Wells, P. S., Wu, C., Nazi, I., & Crowther, M. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13330 · Cited by 96
Jun, M., Lix, L. M., Durand, M., Dahl, M., Paterson, J. M., Dormuth, C. R., Ernst, P., Yao, S., Renoux, C., Tamim, H., et al. (2017) · BMJ · doi:10.1136/bmj.j4323 · Cited by 107
The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis
Naymagon, L., Tremblay, D. A., Zubizarreta, N. J., Moshier, E. L., Troy, K. M., Schiano, T. D., & Mascarenhas, J. O. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001310 · Cited by 95
Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 111
van Gorp, R. H., & Schurgers, L. J. (2015) · Nutrients · doi:10.3390/nu7115479 · Cited by 103
Stefano, V. D., Ruggeri, M., Cervantes, F., Álvarez‐Larrán, A., Iurlo, A., Randi, M. L., Elli, E. M., Finazzi, M. C., Finazzi, G., Zetterberg, E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.85 · Cited by 98
Venous thromboembolism: Recent advancement and future perspective
Yamashita, Y., Morimoto, T., & Kimura, T. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.08.026 · Cited by 106
Kulka, H. C., Zeller, A., Fornaro, J., Wuillemin, W. A., Konstantinides, S., & Christ, M. (2011) · Thieme eBooks · doi:10.1055/b-0034-84633 · Cited by 90
Pengo, V., Banzato, A., Bison, E., Zoppellaro, G., Jose, S. P., & Denas, G. (2015) · Lupus · doi:10.1177/0961203315611495 · Cited by 96
Young, G. A., Lensing, A. W. A., Monagle, P., Male, C., Thelen, K., Willmann, S., Palumbo, J. S., Kumar, R., Nurmeev, I. N., Hege, K. M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14813 · Cited by 103
Klemen, N. D., Feingold, P. L., Hashimoto, B., Wang, M., Kleyman, S., Brackett, A. L., Gross, C. P., & Pei, K. Y. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30211-8 · Cited by 100
Noble, S., Nelson, A., & Seaman, S. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58595 · Cited by 91
Bleeding complications during anticoagulant treatment in patients with cancer
Kamphuisen, P. W., & Beyer‐Westendorf, J. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50009-6 · Cited by 95
Wolf, S. J., Hahn, S. A., Nentwich, L. M., Raja, A. S., Silvers, S. M., & Brown, M. D. (2018) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.03.006 · Cited by 98
Goldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., & Schulman, S. (2016) · Vascular Medicine · doi:10.1177/1358863x16668588 · Cited by 89
Mantha, S. H., & Ansell, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1102-5 · Cited by 92
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 96
Apixaban and dalteparin in active malignancy associated venous thromboembolism: The ADAM VTE Trial
Loprinzi, C. L., Ashrani, A. A., Botero, J. P., Leon-Ferre, R. A., Henkin, S., Lenz, C. J., Le‐Rademacher, J. G., Wysokiński, W. E., & McBane, R. D. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0193 · Cited by 93
Vasanthamohan, L., Boonyawat, K., Chai‐Adisaksopha, C., & Crowther, M. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14156 · Cited by 93
How I treat central venous access device–related upper extremity deep vein thrombosis
Rajasekhar, A., & Streiff, M. B. (2017) · Blood · doi:10.1182/blood-2016-08-693671 · Cited by 94
Old Versus New Oral Anticoagulants: Focus on Pharmacology
Fareed, J., Thethi, I., & Hoppensteadt, D. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134633 · Cited by 97
Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study
Beyer‐Westendorf, J., Tittl, L., Bistervels, I. M., Middeldorp, S., Schaefer, C., Paulus, W. E., Thomas, W., Kemkes‐Matthes, B., Marten, S., & Bornhäuser, M. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30327-6 · Cited by 95
Marshall, A., Levine, M. N., Hill, C. S., Hale, D., Thirlwall, J., Wilkie, V., French, K., Kakkar, A. K., Lokare, A., Maraveyas, A., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14752 · Cited by 87
“The rate of major bleeding was similar between groups (HR = 1.83; 95% CI, 0.68-4.96), but more clinically relevant non-major bleeding (CRNMB) was experienced by patients receiving rivaroxaban compared with dalteparin (HR = 3.76; 95% CI, 1.63-8.69).”
BackgroundInfluentialBamber, L., Wang, M. Y., Prins, M. H., Ciniglio, C., Bauersachs, R., Lensing, A. W. A., & Cano, S. J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-03-0243 · Cited by 86
Piran, S., Traquair, H., Chan, N., Bhagirath, V. C., & Schulman, S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12146 · Cited by 94
Nopp, S., Kraemmer, D., & Ay, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903029 · Cited by 92
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 98
Ageno, W., Squizzato, A., Wells, P. S., Buller, H. R., & Johnson, G. E. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12301 · Cited by 96
Jiménez, D., Lobo, J. L., Monréal, M., Moores, L. K., Oribe, M. A., Barrón, M., Otero, R., Nauffal, D., Rey, R. R., Valle, R., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202900 · Cited by 86
Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy
Rubboli, A., Becattini, C., & Verheugt, F. W. (2011) · World Journal of Cardiology · doi:10.4330/wjc.v3.i11.351 · Cited by 100
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
Eikelboom, J. W., Chan, N., & Bhagirath, V. C. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s63060 · Cited by 95
Cohen, A. T., Gitt, A. K., Bauersachs, R. M., Fronk, E., Laeis, P., Mismetti, P., Monréal, M., Willich, S. N., Bramlage, P., Agnelli, G., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0793 · Cited by 98
Self-citationUpdate on the management of venous thromboembolism
Bartholomew, J. R. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s3.04 · Cited by 91
Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
Willmann, S., Becker, C., Burghaus, R., Coboeken, K., Edginton, A. N., Lippert, J., Siegmund, H., Thelen, K., & Mück, W. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0090-5 · Cited by 89
New oral anticoagulants and regional anaesthesia
Benzon, H. T., Avram, M. J., Green, D., & Bonow, R. O. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet401 · Cited by 93
Dawwas, G. K., Brown, J., Dietrich, E., & Park, H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30191-1 · Cited by 84
Kent, A. P., Brueckmann, M., Fraessdorf, M., Connolly, S. J., Yusuf, S., Eikelboom, J. W., Oldgren, J., Reilly, P. A., Wallentin, L., & Ezekowitz, M. D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.063 · Cited by 83
Grandhi, R., Newman, W. C., Zhang, X., Harrison, G. L., Moran, C. C., Okonkwo, D. O., & Ducruet, A. F. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.08.042 · Cited by 87
Nisio, M. D., Bleker, S. M., Segers, A. E. M., Mercuri, M. F., Schwocho, L. R., Kakkar, A. K., Weitz, J. I., Beyer‐Westendorf, J., Boda, Z., Carrier, M., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-06-0452 · Cited by 83
Ophthalmic regional blocks: management, challenges, and solutions
Palte, H. D. (2015) · Local and Regional Anesthesia · doi:10.2147/lra.s64806 · Cited by 83
Raskob, G. E., Buller, H. R., Prins, M. H., Segers, A. E. M., Shi, M., Schwocho, L. R., van Kranen, R., & Mercuri, M. F. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12230 · Cited by 88
Tummala, R., Kavtaradze, A., Gupta, A., & Ghosh, R. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.056 · Cited by 96
Erkens, P. M. G., Cate, H. T., Buller, H. R., & Prins, M. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042269 · Cited by 84
“Included studies In total, 40 studies [8,9,14,15,16,17,18,19,20,21,22,23,24,25, 26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51] reporting the TTR in 26064 patients treated with VKA for VTE were included in the analyses.”
BackgroundResultInfluentialNakamura, M., Yamada, N., & Ito, M. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.03.012 · Cited by 92
“The limitations of warfarin have stimulated the development of nonvitamin K antagonist oral anticoagulants (NOACs) for the treatment of VTE [10–13] among other indications.”
BackgroundMakam, R. C. P., Hoaglin, D. C., McManus, D. D., Wang, V., Gore, J. M., Spencer, F. A., Pradhan, R., Tran, H. V., Yu, H., & Goldberg, R. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197583 · Cited by 89
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2013.04.016 · Cited by 82
Tittl, L., Endig, S., Marten, S., Reitter, A., Beyer-Westendorf, I., & Beyer‐Westendorf, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.060 · Cited by 86
Kaikita, K., Hosokawa, K., Dahlen, J. R., & Tsujita, K. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1693411 · Cited by 87
Mak, K. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001592 · Cited by 89
Vaglio, S., Prisco, D., Biancofiore, G., Rafanelli, D., Antonioli, P., Lisanti, M., Andreani, L., Basso, L., Velati, C., Grazzini, G., et al. (2016) · PubMed · doi:10.2450/2015.0172-15 · Cited by 98
Projecting future drug expenditures—2012
Hoffman, J. M., Li, E., Doloresco, F., Matusiak, L. M., Hunkler, R. J., Shah, N. D., Vermeulen, L. C., & Schumock, G. T. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110697 · Cited by 87
Thrombosis in cancer patients: etiology, incidence, and management
Sheth, R. A., Niekamp, A., Quencer, K. B., Shamoun, F. E., Knuttinen, M.-G., Naidu, S., & Öklü, R. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.11.02 · Cited by 80
Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management
Donnellan, E., Kevane, B., Bird, B., & Áinle, F. N. (2014) · Current Oncology · doi:10.3747/co.21.1864 · Cited by 91
Reversal of antithrombotic agents
Bauer, K. A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23165 · Cited by 80
The perioperative management of new direct oral anticoagulants: a question without answers
Castillo, J., Andrés, J. A. D., Gomar, C. G., Gómez‐Luque, A., Hidalgo, F., Llau, J. V., Sierra, P., Torres, L. M., & Ferrandis, R. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0868 · Cited by 85
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.